G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of $0.14, $0.36 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $42.4 million versus the consensus estimate of $28.95 million.

G1 today reiterated its full year 2023 net revenue guidance. The Company expects to generate between $50 million and $60 million in COSELA net revenue in 2023

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Omega Flex (OFLX) Tops Q2 EPS by 27c
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance